Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Elicera Therapeutics

2.80 SEK+3.52 %9/9 10:59
Less than 1K followers

ELIC

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor views
Compare
+3.52 %
+10.47 %
+10.04 %
-55.87 %
-45.05 %
-58.06 %
+13.83 %
-58.90 %
-53.73 %

Elicera Therapeutics AB is a clinical phase cell and gene therapy company that develops the next generation of immuno-oncology treatments. The work is based on high-profile long-standing research conducted by Professor Magnus Essand's research group at Uppsala University and has resulted in the development of four drug candidates, including two CAR T cells and two oncolytic viruses.

Read more
Market cap
186.53M SEK
Turnover
724.45K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Research
Press releases
3rd party
ShowingAll content types

Revenue and EBIT-%

Revenue K

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
27/11
2026

Interim report Q3'26

16/2
2027

Annual report '26

11/5
2027

Interim report Q1'27

Press release2026-09-09 08:45

Elicera Therapeutics får säkerhetskommitténs rekommendation att använda högsta dosen av ELC-301 när CARMA går mot fas IIa vid B-cellslymfom

Elicera Therapeutics
Press release2026-09-09 08:45

Elicera Therapeutics Receives Safety Committee Recommendation to Use Highest ELC-301 Dose as CARMA Moves Toward Phase IIa in B-cell Lymphoma

Elicera Therapeutics
Press release2026-09-01 14:06

Elicera Therapeutics får sitt första besked om patentbeviljande för ELC-201 - japanskt patent som skyddar den onkolytiska viruskandidaten mot solida tumörer

Elicera Therapeutics

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release2026-09-01 14:06

Elicera Therapeutics receives its first notice of patent allowance for ELC-201 - a Japanese patent protecting the oncolytic virus candidate against solid tumors

Elicera Therapeutics
Press release2026-08-28 16:25

Carlsquare: Analysuppdatering Elicera Therapeutics kv2 2026: Bra momentum i CARMA-studien

Elicera Therapeutics
Press release2026-08-28 14:02

DNB Carnegie Access: Elicera Therapeutics: Financed for next clinical steps – Q2 review

Elicera Therapeutics
Press release2026-08-28 10:08

Elicera Therapeutics får besked om beviljande av USA-patent som skyddar CAR T-cellskandidaten ELC-401

Elicera Therapeutics
Press release2026-08-28 10:08

Elicera Therapeutics receives Notice of Allowance for U.S. patent application protecting the ELC-401 CAR T-cell candidate

Elicera Therapeutics
Regulatory press release2026-08-28 08:02

Elicera Therapeutics AB (publ) Interim Report 1 January - 30 June 2026

Elicera Therapeutics
Regulatory press release2026-08-28 08:02

Elicera Therapeutics AB (publ) Delårsbokslut 1 januari - 30 juni 2026

Elicera Therapeutics
Press release2026-08-18 09:31

DNB Carnegie Access: Elicera Therapeutics: New CEO announced

Elicera Therapeutics
Regulatory press release2026-08-18 08:30

Elicera Therapeutics utser Johan Liwing till ny VD

Elicera Therapeutics
Regulatory press release2026-08-18 08:30

Elicera Therapeutics appoints Johan Liwing as new CEO

Elicera Therapeutics
Press release2026-08-14 13:48

Rättelse - Elicera Therapeutics: Sista patienten behandlad i fas I-delen av CARMA-studien - tumörsvar hos 10 av 11 hittills utvärderade patienter

Elicera Therapeutics
Press release2026-08-14 13:48

Correction - Elicera Therapeutics: Last patient treated in the Phase I part of the CARMA study - tumor responses in 10 of 11 patients evaluated to date

Elicera Therapeutics
Press release2026-08-12 07:33

DNB Carnegie Access: Elicera Therapeutics: CARMA-trial delivers another encouraging update

Elicera Therapeutics
Press release2026-08-11 14:50

Carlsquare: Mrkt BUZZ Elicera Therapeutics: Lovande data från upploppet av CARMA-studiens första del

Elicera Therapeutics
Press release2026-08-11 12:54

Elicera Therapeutics: Sista patienten behandlad i fas I-delen av CARMA-studien - tumörsvar hos 10 av 11 hittills utvärderade patienter

Elicera Therapeutics
Press release2026-08-11 12:54

Elicera Therapeutics: Last patient treated in the Phase I part of the CARMA study - tumor responses in 10 of 11 patients evaluated to date

Elicera Therapeutics
Regulatory press release2026-07-24 08:01

Elicera Therapeutics samlar ledningen i Uppsala - VD-skifte inleds och rekrytering av ny VD har påbörjats

Elicera Therapeutics